CoChat
Sign Up
Cited by 107

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

What causes amyotrophic lateral sclerosis?

Martin, Sarah, Al Khleifat, Ahmad, Al-Chalabi, Ammar·2017·F1000Research
DOI 10.12688/f1000research.10476.1PMC PMC5373425
Open this paper in CoChat — free account

Abstract

Amyotrophic lateral sclerosis is a neurodegenerative disease predominantly affecting upper and lower motor neurons, resulting in progressive paralysis and death from respiratory failure within 2 to 3 years. The peak age of onset is 55 to 70 years, with a male predominance. The causes of amyotrophic lateral sclerosis are only partly known, but they include some environmental risk factors as well as several genes that have been identified as harbouring disease-associated variation. Here we review the nature, epidemiology, genetic associations, and environmental exposures associated with amyotrophic lateral sclerosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.12688/f1000research.10476.1

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. The time course of amyotrophic lateral sclerosis (ALS). Time is represented along the x-axis; physical health and molecular damage are represented along the y-axis. With time, molecular damage increases in a step-wise way until it reaches a threshold, at which point physical health declines, representing disease onset. People with a family history of ALS may have a large genetic predisposition to ALS and so need fewer steps to reach the level of molecular damage that causes disease, corresponding to a younger age of onset. Lack of exposure to sufficient risk factors means that the disease does not manifest, even if a genetic cause is present, explaining reduced penetrance. There is not a 1:1 mapping of risk factors and steps, as the steps represent molecular hits that lead to cellular damage rather than actual exposures. Once physical symptoms have started, progression shows a log-linear decline until the onset of respiratory symptoms, where decline is exponential. Clinical and functional involvement can be measured by the King’s clinical staging and Milano-Torino staging (MiToS) systems. A dotted line represents the hypothetical trajectory in an unaffected individual. Black arrows represent genetic and environmental risk factors. Numbers indicate remaining molecular hits until disease onset.
Figure 1. The time course of amyotrophic lateral sclerosis (ALS). Time is represented along the x-axis; physical health and molecular damage are represented along the y-axis. With time, molecular damage increases in a step-wise way until it reaches a threshold, at which point physical health declines, representing disease onset. People with a family history of ALS may have a large genetic predisposition to ALS and so need fewer steps to reach the level of molecular damage that causes disease, corresponding to a younger age of onset. Lack of exposure to sufficient risk factors means that the disease does not manifest, even if a genetic cause is present, explaining reduced penetrance. There is not a 1:1 mapping of risk factors and steps, as the steps represent molecular hits that lead to cellular damage rather than actual exposures. Once physical symptoms have started, progression shows a log-linear decline until the onset of respiratory symptoms, where decline is exponential. Clinical and functional involvement can be measured by the King’s clinical staging and Milano-Torino staging (MiToS) systems. A dotted line represents the hypothetical trajectory in an unaffected individual. Black arrows represent genetic and environmental risk factors. Numbers indicate remaining molecular hits until disease onset.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 104

  1. K Talbot, 2009, Motor neuron disease: the bare essentials., Pract Neurol., 9, 303-09, 10.1136/jnnp.2009.188151 · DOI
  2. E Pupillo, 2014, Long-term survival in amyotrophic lateral sclerosis: a population-based study., Ann Neurol., 75, 287-97, 10.1002/ana.24096 · DOI
  3. A Chiò, 2013, Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature., Neuroepidemiology., 41, 118-30, 10.1159/000351153 · DOI · Paper page
  4. A Alonso, 2009, Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study., Eur J Neurol., 16, 745-51, 10.1111/j.1468-1331.2009.02586.x · DOI · Paper page
  5. C Johnston, 2006, Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London., J Neurol., 253, 1642-43, 10.1007/s00415-006-0195-y · DOI
  6. A Alonso, 2008, Temporal trends in the incidence of multiple sclerosis: a systematic review., Neurology., 71, 129-35, 10.1212/01.wnl.0000316802.35974.34 · DOI
  7. J Mitchell, 2010, Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)--a 20-year review: can we do better?, Amyotroph Lateral Scler., 11, 537-41, 10.3109/17482968.2010.495158 · DOI
  8. J Lee, 1995, Prognosis of amyotrophic lateral sclerosis and the effect of referral selection., J Neurol Sci., 132, 207-15, 10.1016/0022-510X(95)00154-T · DOI
  9. E Sorenson, 2007, Effect of referral bias on assessing survival in ALS., Neurology., 68, 600-2, 10.1212/01.wnl.0000254501.58158.e7 · DOI
  10. G Logroscino, 2008, Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues., J Neurol Neurosurg Psychiatry., 79, 6-11, 10.1136/jnnp.2006.104828 · DOI
  11. J Wolf, 2014, Variability and prognostic relevance of different phenotypes in amyotrophic lateral sclerosis - data from a population-based registry., J Neurol Sci., 345, 164-67, 10.1016/j.jns.2014.07.033 · DOI
  12. L Wijesekera, 2009, Natural history and clinical features of the flail arm and flail leg ALS variants., Neurology., 72, 1087-94, 10.1212/01.wnl.0000345041.83406.a2 · DOI
  13. J Ravits, 2009, ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration., Neurology., 73, 805-11, 10.1212/WNL.0b013e3181b6bbbd · DOI
  14. E Bidhendi, 2016, Two superoxide dismutase prion strains transmit amyotrophic lateral sclerosis-like disease., J Clin Invest., 126, 2249-53, 10.1172/JCI84360 · DOI
  15. G Clarke, 2001, Inherited neurodegenerative diseases: the one-hit model of neurodegeneration., Hum Mol Genet., 10, 2269-75, 10.1093/hmg/10.20.2269 · DOI
  16. G Liu, 2012, Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1., Am J Neurodegener Dis., 1, 60-74
  17. S Nandedkar, 2010, Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease., Muscle Nerve., 42, 798-807, 10.1002/mus.21824 · DOI
  18. N Atassi, 2011, Advanced statistical methods to study the effects of gastric tube and non-invasive ventilation on functional decline and survival in amyotrophic lateral sclerosis., Amyotroph Lateral Scler., 12, 272-77, 10.3109/17482968.2011.577786 · DOI
  19. J Costa, 2012, Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review., Arch Neurol., 69, 1410-16, 10.1001/archneurol.2012.254 · DOI · Paper page
  20. N Geevasinga, 2016, Revisiting early diagnosis in ALS., Clin Neurophysiol., 127, e13-e14, 10.1016/j.clinph.2015.11.031 · DOI
  21. N Geevasinga, 2016, Diagnostic criteria in amyotrophic lateral sclerosis: A multicenter prospective study., Neurology., 87, 684-90, 10.1212/WNL.0000000000002988 · DOI
  22. B Brooks, 1994, El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors., J Neurol Sci., 124, 96-107, 10.1016/0022-510X(94)90191-0 · DOI
  23. M de Carvalho, 2008, Electrodiagnostic criteria for diagnosis of ALS., Clin Neurophysiol., 119, 497-503, 10.1016/j.clinph.2007.09.143 · DOI
  24. R Miller, 1999, Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research., J Neurol Sci., 169, 2-12, 10.1016/S0022-510X(99)00209-9 · DOI
  25. M Schrooten, 2011, Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study., Ann Neurol., 70, 79-83, 10.1002/ana.22380 · DOI
  26. J Rooney, 2016, What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis., J Neurol Neurosurg Psychiatry., 10.1136/jnnp-2016-314661 · DOI
  27. A Chiò, 2015, Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis., J Neurol Neurosurg Psychiatry., 86, 38-44, 10.1136/jnnp-2013-306589 · DOI
  28. J Roche, 2012, A proposed staging system for amyotrophic lateral sclerosis., Brain., 135, 847-52, 10.1093/brain/awr351 · DOI
  29. R Balendra, 2014, Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale., Amyotroph Lateral Scler Frontotemporal Degener., 15, 279-84, 10.3109/21678421.2014.897357 · DOI
  30. T Fang, 2017, Comparison of the King’s and MiToS staging systems for ALS., Amyotroph Lateral Scler Frontotemporal Degener., 1-6, 10.1080/21678421.2016.1265565 · DOI
  31. R Balendra, 2015, Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials., J Neurol Neurosurg Psychiatry., 86, 45-9, 10.1136/jnnp-2013-306865 · DOI
  32. D Ferraro, 2016, Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study., Eur J Neurol., 23, 1426-32, 10.1111/ene.13053 · DOI
  33. B Swinnen, 2014, The phenotypic variability of amyotrophic lateral sclerosis., Nat Rev Neurol., 10, 661-70, 10.1038/nrneurol.2014.184 · DOI
  34. A Montuschi, 2015, Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy., J Neurol Neurosurg Psychiatry., 86, 168-73, 10.1136/jnnp-2013-307223 · DOI
  35. G Rippon, 2006, An observational study of cognitive impairment in amyotrophic lateral sclerosis., Arch Neurol., 63, 345-52, 10.1001/archneur.63.3.345 · DOI
  36. C Lomen-Hoerth, 2002, The overlap of amyotrophic lateral sclerosis and frontotemporal dementia., Neurology., 59, 1077-9, 10.1212/WNL.59.7.1077 · DOI
  37. M Strong, 2008, The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis., Amyotroph Lateral Scler., 9, 323-38, 10.1080/17482960802372371 · DOI
  38. S Abrahams, 2014, Screening for cognition and behaviour changes in ALS., Amyotroph Lateral Scler Frontotemporal Degener., 15, 9-14, 10.3109/21678421.2013.805784 · DOI
  39. E Niven, 2015, Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disorders., Amyotroph Lateral Scler Frontotemporal Degener., 16, 172-79, 10.3109/21678421.2015.1030430 · DOI
  40. S Tazen, 2013, Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2., JAMA Neurol., 70, 1302-4, 10.1001/jamaneurol.2013.443 · DOI
  41. M Etemadifar, 2012, Multiple sclerosis and amyotrophic lateral sclerosis: is there a link?, Mult Scler., 18, 902-4, 10.1177/1352458511427719 · DOI
  42. R Howland, 1990, Schizophrenia and amyotrophic lateral sclerosis., Compr Psychiatry., 31, 327-36, 10.1016/0010-440X(90)90039-U · DOI
  43. J Cooper-Knock, 2014, The widening spectrum of C9ORF72-related disease; Genotype/phenotype correlations and potential modifiers of clinical phenotype., Acta Neuropathol., 127, 333-45, 10.1007/s00401-014-1251-9 · DOI
  44. A Neuenschwander, 2014, Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis., JAMA Neurol., 71, 1529-34, 10.1001/jamaneurol.2014.2082 · DOI
  45. M Polkey, 2017, Respiratory Muscle Strength as a Predictive Biomarker for Survival in Amyotrophic Lateral Sclerosis., Am J Respir Crit Care Med., 195, 86-95, 10.1164/rccm.201604-0848OC · DOI
  46. A Chiò, 2014, Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study., JAMA Neurol., 71, 1134-42, 10.1001/jamaneurol.2014.1129 · DOI
  47. C Lu, 2015, Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis., Neurology., 84, 2247-57, 10.1212/WNL.0000000000001642 · DOI · Paper page
  48. A Calvo, 2016, Factors predicting survival in ALS: a multicenter Italian study., J Neurol., 264, 54-63, 10.1007/s00415-016-8313-y · DOI · Paper page
  49. M Elamin, 2011, Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia., Neurology., 76, 1263-9, 10.1212/WNL.0b013e318214359f · DOI
  50. B Marin, 2016, Population-Based Evidence that Survival in Amyotrophic Lateral Sclerosis is Related to Weight Loss at Diagnosis., Neurodegener Dis., 16, 225-34, 10.1159/000442444 · DOI · Paper page
  51. M Moura, 2015, Prognostic Factors in Amyotrophic Lateral Sclerosis: A Population-Based Study., PLoS One., 10, e0141500, 10.1371/journal.pone.0141500 · DOI
  52. J Wolf, 2015, Factors Predicting Survival in ALS Patients--Data from a Population-Based Registry in Rhineland-Palatinate, Germany., Neuroepidemiology., 44, 149-55, 10.1159/000381625 · DOI
  53. J Wolf, 2014, Factors predicting one-year mortality in amyotrophic lateral sclerosis patients--data from a population-based registry., BMC Neurol., 14, 197, 10.1186/s12883-014-0197-9 · DOI · Paper page
  54. A Czaplinski, 2006, Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population., J Neurol Neurosurg Psychiatry., 77, 390-2, 10.1136/jnnp.2005.072660 · DOI
  55. J Knibb, 2016, A clinical tool for predicting survival in ALS., J Neurol Neurosurg Psychiatry., 87, 1361-1367, 10.1136/jnnp-2015-312908 · DOI
  56. C Shoesmith, 2007, Prognosis of amyotrophic lateral sclerosis with respiratory onset., J Neurol Neurosurg Psychiatry., 78, 629-31, 10.1136/jnnp.2006.103564 · DOI
  57. A Czaplinski, 2006, Amyotrophic lateral sclerosis: early predictors of prolonged survival., J Neurol., 253, 1428-36, 10.1007/s00415-006-0226-8 · DOI
  58. F Diekstra, 2012, UNC13A is a modifier of survival in amyotrophic lateral sclerosis., Neurobiol Aging., 33, 630.e3-8, 10.1016/j.neurobiolaging.2011.10.029 · DOI
  59. B Gaastra, 2016, Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis., Amyotroph Lateral Scler Frontotemporal Degener., 17, 593-99, 10.1080/21678421.2016.1213852 · DOI
  60. I Fogh, 2016, Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis., JAMA Neurol., 73, 812-20, 10.1001/jamaneurol.2016.1114 · DOI
  61. P Andersen, 2011, Clinical genetics of amyotrophic lateral sclerosis: what do we really know?, Nat Rev Neurol., 7, 603-15, 10.1038/nrneurol.2011.150 · DOI · Paper page
  62. P Andersen, 1995, Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase., Nat Genet., 10, 61-6, 10.1038/ng0595-61 · DOI
  63. M Cudkowicz, 1997, Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis., Ann Neurol., 41, 210-21, 10.1002/ana.410410212 · DOI
  64. A Taylor, 2016, Predicting disease progression in amyotrophic lateral sclerosis., Ann Clin Transl Neurol., 3, 866-75, 10.1002/acn3.348 · DOI
  65. Y Sato, 2015, Prediction of prognosis of ALS: Importance of active denervation findings of the cervical-upper limb area and trunk area., Intractable Rare Dis Res., 4, 181-9, 10.5582/irdr.2015.01043 · DOI
  66. A Carreiro, 2015, Prognostic models based on patient snapshots and time windows: Predicting disease progression to assisted ventilation in Amyotrophic Lateral Sclerosis., J Biomed Inform., 58, 133-44, 10.1016/j.jbi.2015.09.021 · DOI
  67. A Al-Chalabi, 2010, An estimate of amyotrophic lateral sclerosis heritability using twin data., J Neurol Neurosurg Psychiatry., 81, 1324-26, 10.1136/jnnp.2010.207464 · DOI
  68. A Al-Chalabi, 2011, Modelling the effects of penetrance and family size on rates of sporadic and familial disease., Hum Hered., 71, 281-88, 10.1159/000330167 · DOI
  69. E Majounie, 2012, Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study., Lancet Neurol., 11, 323-30, 10.1016/S1474-4422(12)70043-1 · DOI · Paper page
  70. W van Rheenen, 2016, Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis., Nat Genet., 48, 1043-48, 10.1038/ng.3622 · DOI
  71. A Chiò, 2012, Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9orf72., Brain., 135, 784-93, 10.1093/brain/awr366 · DOI
  72. K Kenna, 2016, NEK1 variants confer susceptibility to amyotrophic lateral sclerosis., Nat Genet., 48, 1037-42, 10.1038/ng.3626 · DOI
  73. K Williams, 2015, Novel TBK1 truncating mutation in a familial amyotrophic lateral sclerosis patient of Chinese origin., Neurobiol Aging., 36, 3334.e1-34.e5, 10.1016/j.neurobiolaging.2015.08.013 · DOI
  74. D Rosen, 1993, Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis., Nature., 362, 59-62, 10.1038/362059a0 · DOI · Paper page
  75. S Kaur, 2016, Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis., Gene., 577, 109-18, 10.1016/j.gene.2015.11.049 · DOI
  76. D Cleveland, 1996, Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease., Neurology., 47, S54-61, 10.1212/WNL.47.4_Suppl_2.54S · DOI
  77. C Lagier-Tourenne, 2012, Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs., Nat Neurosci., 15, 1488-97, 10.1038/nn.3230 · DOI
  78. V Van Deerlin, 2008, TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis., Lancet Neurol., 7, 409-16, 10.1016/S1474-4422(08)70071-1 · DOI · Paper page
  79. C Vance, 2006, Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2–21.3., Brain., 129, 868-76, 10.1093/brain/awl030 · DOI
  80. M Morita, 2006, A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia., Neurology., 66, 839-44, 10.1212/01.wnl.0000200048.53766.b4 · DOI
  81. H Laaksovirta, 2010, Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study., Lancet Neurol., 9, 978-85, 10.1016/S1474-4422(10)70184-8 · DOI
  82. A Shatunov, 2010, Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study., Lancet Neurol., 9, 986-94, 10.1016/S1474-4422(10)70197-6 · DOI
  83. M van Es, 2009, Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis., Nat Genet., 41, 1083-7, 10.1038/ng.442 · DOI
  84. J Kosmicki, 2016, Discovery of rare variants for complex phenotypes., Hum Genet., 135, 625-34, 10.1007/s00439-016-1679-1 · DOI
  85. R McLaughlin, 2015, Heritability of Amyotrophic Lateral Sclerosis: Insights From Disparate Numbers., JAMA Neurol., 72, 857-57, 10.1001/jamaneurol.2014.4049 · DOI
  86. A Al-Chalabi, 2013, The epidemiology of ALS: a conspiracy of genes, environment and time., Nat Rev Neurol., 9, 617-28, 10.1038/nrneurol.2013.203 · DOI
  87. A Alonso, 2010, Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis., J Neurol Neurosurg Psychiatry., 81, 1249-52, 10.1136/jnnp.2009.180232 · DOI · Paper page
  88. J Beard, 2015, Military Service, Deployments, and Exposures in Relation to Amyotrophic Lateral Sclerosis Etiology and Survival., Epidemiol Rev., 37, 55-70, 10.1093/epirev/mxu001 · DOI
  89. N Scarmeas, 2002, Premorbid weight, body mass, and varsity athletics in ALS., Neurology., 59, 773-5, 10.1212/WNL.59.5.773 · DOI · Paper page
  90. E Lacorte, 2016, Physical activity, and physical activity related to sports, leisure and occupational activity as risk factors for ALS: A systematic review., Neurosci Biobehav Rev., 66, 61-79, 10.1016/j.neubiorev.2016.04.007 · DOI
  91. K Abhinav, 2007, Electrical injury and amyotrophic lateral sclerosis: a systematic review of the literature., J Neurol Neurosurg Psychiatry., 78, 450-53, 10.1136/jnnp.2006.104414 · DOI
  92. H Fischer, 2015, Occupational Exposure to Electric Shocks and Magnetic Fields and Amyotrophic Lateral Sclerosis in Sweden., Epidemiology., 26, 824-30, 10.1097/EDE.0000000000000365 · DOI
  93. V Bozzoni, 2016, Amyotrophic lateral sclerosis and environmental factors., Funct Neurol., 31, 7-19, 10.11138/FNeur/2016.31.1.007 · DOI
  94. A Delzor, 2014, Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme., BMJ Open., 4, e005528, 10.1136/bmjopen-2014-005528 · DOI
  95. J Rooney, 2016, No association between soil constituents and amyotrophic lateral sclerosis relative risk in Ireland., Environ Res., 147, 102-7, 10.1016/j.envres.2016.01.038 · DOI
  96. N Sutedja, 2009, Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review., Amyotroph Lateral Scler., 10, 302-9, 10.3109/17482960802455416 · DOI
  97. A Malek, 2015, Exposure to hazardous air pollutants and the risk of amyotrophic lateral sclerosis., Environ Pollut., 197, 181-6, 10.1016/j.envpol.2014.12.010 · DOI
  98. M Evans, 2013, Inflammation and neurovascular changes in amyotrophic lateral sclerosis., Mol Cell Neurosci., 53, 34-41, 10.1016/j.mcn.2012.10.008 · DOI
  99. W Zhao, 2013, Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis., J Neuroimmune Pharmacol., 8, 888-99, 10.1007/s11481-013-9489-x · DOI
  100. J Henkel, 2013, Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival., EMBO Mol Med., 5, 64-79, 10.1002/emmm.201201544 · DOI
  101. S Mantovani, 2009, Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process., J Neuroimmunol., 210, 73-79, 10.1016/j.jneuroim.2009.02.012 · DOI
  102. M Rentzos, 2012, Alterations of T cell subsets in ALS: A systemic immune activation?, Acta Neurol Scand., 125, 260-64, 10.1111/j.1600-0404.2011.01528.x · DOI
  103. A McCormick, 2008, Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate., Neurology., 70, 278-83, 10.1212/01.wnl.0000297552.13219.b4 · DOI · Paper page
  104. A Al-Chalabi, 2014, Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study., Lancet Neurol., 13, 1108-13, 10.1016/S1474-4422(14)70219-4 · DOI · Paper page

Cited by

Sorted by citations

See all 107

Metadata

Authors
Martin, S., Al Khleifat, A., & Al-Chalabi, A.
ORCID
Martin, Sarah
Venue
F1000Research
Publisher
F1000 Research Ltd
Published
2017-03-28
Volume
6
Pages
371
ISSN
2046-1402
DOI
10.12688/f1000research.10476.1
PMC
PMC5373425
Cited by
107
References
7
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review